SNGX

Soligenix Inc

An independent committee recommended stopping Soligenix’s late-stage trial to treat lymphoma due to a lack of effectiveness.

Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impacts SNGX and next steps.read more...

US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63...

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial...

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader  Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that […]

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behçet’s disease, […]

Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides  both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy, reinforcing the company’s focus on developing innovative treatments for serious […]

Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy Positive Clinical Results...

Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide […]